SCHEMBL22818589

SCHEMBL22818589

O=S(=O)(c1cc(C(O)Nc2cc(F)c(F)c(F)c2)ccc1F)N1CCC(O)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.53
▸ CYP2D6 P10635 3/20 0.53
▸ CYP2C9 P11712 3/20 0.53
▸ CYP2C19 P33261 3/20 0.53
▸ KCNH2 Q12809 2/20 0.53
▸ CYP1A2 P05177 2/20 0.53
▸ MAPT P10636 5/20 0.41
▸ TP53 P04637 3/20 0.41
▸ PKM P14618 1/20 0.40
▸ LMNA P02545 3/20 0.39
▸ TSHR P16473 2/20 0.39
▸ ALOX5AP P20292 2/20 0.38
▸ FEN1 P39748 2/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ CCR1 P32246 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20647810 0.89 CYP3A4 (0.41) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL20647809 0.88 CYP3A4 (0.41) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL20647789 0.87 CYP2C9 (0.41) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL19841949 0.86 MAPT (0.43) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL20647675 0.86 CYP3A4 (0.41) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL20647787 0.84 CYP3A4 (0.40) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL20647780 0.82 MAPT (0.41) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL19841965 0.81 HSD11B1 (0.43) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL20647693 0.79 CYP3A4 (0.36) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2
SCHEMBL20647803 0.79 CYP3A4 (0.35) CYP3A4CYP2D6CYP2C9CYP2C19KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3848026-A1 COMBINATIONS AND METHODS COMPRISING A CAPSID ASSEMBLY INHIBITOR Novira Therapeutics Inc. (US) 2021-07-14 — — EP disclosed
WO-2020255012-A1 COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND CAPSID ASSEMBLY MODULATORS BEING SULFONAMIDE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2020-12-24 — — WO disclosed
Send feedback